184 related articles for article (PubMed ID: 36596381)
1. Hybridoma-derived neutralizing monoclonal antibodies against Beta and Delta variants of SARS-CoV-2 in vivo.
Wang Q; Peng L; Nie Y; Shu Y; Zhang H; Song Z; Li Y; Hu H; Li L; Wang X; Liu J; Li J; Shi Z; Deng F; Guo Y; Zhou Y; Yan B; Hu Z; Wang M
Virol Sin; 2023 Apr; 38(2):257-267. PubMed ID: 36596381
[TBL] [Abstract][Full Text] [Related]
2. Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.
Mariotti S; Capocefalo A; Chiantore MV; Iacobino A; Teloni R; De Angelis ML; Gallinaro A; Pirillo MF; Borghi M; Canitano A; Michelini Z; Baggieri M; Marchi A; Bucci P; McKay PF; Acchioni C; Sandini S; Sgarbanti M; Tosini F; Di Virgilio A; Venturi G; Marino F; Esposito V; Di Bonito P; Magurano F; Cara A; Negri D; Nisini R
Front Immunol; 2021; 12():750386. PubMed ID: 34764961
[TBL] [Abstract][Full Text] [Related]
3. Distinct in vitro and in vivo neutralization profiles of monoclonal antibodies elicited by the receptor binding domain of the ancestral SARS-CoV-2.
Kwon HJ; Zhang J; Kosikova M; Tang W; Ortega-Rodriguez U; Peng H; Meseda CA; Pedro CL; Schmeisser F; Lu J; Kang I; Zhou B; Davis CT; Wentworth DE; Chen WH; Shriver MC; Barnes RS; Pasetti MF; Weir JP; Chen B; Xie H
J Med Virol; 2023 Mar; 95(3):e28673. PubMed ID: 36916782
[TBL] [Abstract][Full Text] [Related]
4. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
5. Antibody cocktail effective against variants of SARS-CoV-2.
Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
7. Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies.
Maghsood F; Amiri MM; Zarnani AH; Salimi V; Kardar GA; Khoshnoodi J; Mobini M; Ahmadi Zare H; Ghaderi A; Jeddi-Tehrani M; Schmidt S; Laumond G; Moog C; Shokri F
Front Med (Lausanne); 2022; 9():973036. PubMed ID: 36148457
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.
Ko SH; Chen WY; Su SC; Lin HT; Ke FY; Liang KH; Hsu FF; Kumari M; Fu CY; Wu HC
J Biomed Sci; 2022 Dec; 29(1):108. PubMed ID: 36550570
[TBL] [Abstract][Full Text] [Related]
9. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
[TBL] [Abstract][Full Text] [Related]
10. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants.
Makdasi E; Zvi A; Alcalay R; Noy-Porat T; Peretz E; Mechaly A; Levy Y; Epstein E; Chitlaru T; Tennenhouse A; Aftalion M; Gur D; Paran N; Tamir H; Zimhony O; Weiss S; Mandelboim M; Mendelson E; Zuckerman N; Nemet I; Kliker L; Yitzhaki S; Shapira SC; Israely T; Fleishman SJ; Mazor O; Rosenfeld R
Cell Rep; 2021 Sep; 36(10):109679. PubMed ID: 34464610
[TBL] [Abstract][Full Text] [Related]
11. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
[TBL] [Abstract][Full Text] [Related]
13. Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody.
Piepenbrink MS; Park JG; Deshpande A; Loos A; Ye C; Basu M; Sarkar S; Khalil AM; Chauvin D; Woo J; Lovalenti P; Erdmann NB; Goepfert PA; Truong VL; Bowen RA; Walter MR; Martinez-Sobrido L; Kobie JJ
PLoS Pathog; 2022 Jul; 18(7):e1010691. PubMed ID: 35862475
[TBL] [Abstract][Full Text] [Related]
14. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2.
Ji Y; Zhang Q; Cheng L; Ge J; Wang R; Fang M; Mucker EM; Chen P; Ma J; Zhang R; Li C; Hammond H; Baracco L; Holbrook M; Frieman M; Zhang Z; Wang X; Hooper JW; Zhang L; Zhu Q
Front Immunol; 2022; 13():980435. PubMed ID: 36189212
[TBL] [Abstract][Full Text] [Related]
15. RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.
Shi J; Zheng J; Zhang X; Tai W; Odle AE; Perlman S; Du L
Transl Res; 2022 Oct; 248():11-21. PubMed ID: 35489692
[TBL] [Abstract][Full Text] [Related]
16. Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain.
Gao X; Fan L; Zheng B; Li H; Wang J; Zhang L; Li J; Zhu F
Hum Vaccin Immunother; 2022 Nov; 18(5):2055373. PubMed ID: 35417303
[TBL] [Abstract][Full Text] [Related]
17. Broad-spectrum humanized monoclonal neutralizing antibody against SARS-CoV-2 variants, including the Omicron variant.
Wen K; Cai JP; Fan X; Zhang X; Luo C; Tang KM; Shuai H; Chen LL; Zhang RR; Situ J; Tsoi HW; Wang K; Chan JF; Yuan S; Yuen KY; Zhou H; To KK
Front Cell Infect Microbiol; 2023; 13():1213806. PubMed ID: 37645378
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies.
Qiu H; Yuan XY; Cabral T; Manguiat K; Robinson A; Wood H; Grant C; McQueen P; Westmacott G; Beniac DR; Lin L; Carpenter M; Kobasa D; Gräfenhan T
Antiviral Res; 2021 Dec; 196():105206. PubMed ID: 34762975
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of SARS-CoV-2 reactive and neutralizing antibodies from humanized CAMouse
Yang X; Chi H; Wu M; Wang Z; Lang Q; Han Q; Wang X; Liu X; Li Y; Wang X; Huang N; Bi J; Liang H; Gao Y; Zhao Y; Feng N; Yang S; Wang T; Xia X; Ge L
Front Immunol; 2022; 13():992787. PubMed ID: 36211410
[TBL] [Abstract][Full Text] [Related]
20. Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies.
Li R; Mor M; Ma B; Clark AE; Alter J; Werbner M; Lee JC; Leibel SL; Carlin AF; Dessau M; Gal-Tanamy M; Croker BA; Xiang Y; Freund NT
Commun Biol; 2022 Aug; 5(1):789. PubMed ID: 35931732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
